.jpg)
Israel’s Evogene to sell Lavie Bio's main operations to ICL
Evogene announced a deal for ICL to acquire most of its subsidiary Lavie Bio and Evogene's MicroBoost AI for AG platform. Expected to close in second quarter, the deal includes Lavie Bio’s core team, technology platform, microbial bank, development programmes, and products. Existing Lavie Bio partner agreements remain separate. The move aims to boost innovation in the ag-biologicals sector.
Evogene announced a deal for ICL to acquire most of its subsidiary Lavie Bio and Evogene's MicroBoost AI for AG platform.
Expected to close in second quarter, the deal includes Lavie Bio’s core team, technology platform, microbial bank, development programmes, and products.
Existing Lavie Bio partner agreements remain separate.
The move aims to boost innovation in the ag-biologicals sector.
